T
21.47
0.35 (1.66%)
| Penutupan Terdahulu | 21.12 |
| Jumlah Dagangan | 2,538,336 |
| Harga / Pendapatan (P/E Ke hadapan) | 12.95 |
| Harga / Jualan (P/S) | 2.24 |
| Harga / Buku (P/B) | 1.43 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 4.61% |
| Margin Keuntungan | 2.36% |
| Margin Operasi (TTM) | 11.68% |
| EPS Cair (TTM) | 0.230 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 0.20% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -77.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 73.36% |
| Nisbah Semasa (MRQ) | 1.01 |
| Aliran Tunai Operasi (OCF TTM) | 1.06 T |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 735.62 B |
| Pulangan Atas Aset (ROA TTM) | 2.40% |
| Pulangan Atas Ekuiti (ROE TTM) | 1.52% |
AISkor Stockmoo
| Nilai 30% | -0.5 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.5 |
| Masa 30% | 3.0 |
| AI Technical info | NA |
| Osilator Teknikal info | 4.0 |
| Purata Bergerak Teknikal info | 1.5 |
| Sentimen 20% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -0.8 |
| Aktiviti Orang Dalam info | -0.8 |
| Aliran Institusi info | NA |
| Persekitaran | ×0.85 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -4.0% |
| Persetujuan Tonggak | ×0.99 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -3.0 |
| Skor Akhir | 0.50 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Takeda Pharmaceutical Company L | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| TAK | - | 4.61% | - | 1.43 |
| RDY | - | 0.68% | - | 3.07 |
| HLN | - | 2.14% | - | 1.84 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
| HIMS | - | - | - | 18.72 |
|
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 0.01% |
| % Dimiliki oleh Institusi | 2.30% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BITETTI TERESA MARIE | - | 20.87 | -46,609 | -972,730 |
| PLATFORD GILES RICHARD | - | 21.06 | -55,617 | -1,171,294 |
| Jumlah Keseluruhan Kuantiti Bersih | -102,226 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,144,024 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 20.97 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PLATFORD GILES RICHARD | Pegawai | 04 Nov 2026 | Jual (-) | 55,617 | 21.06 | 1,171,294 |
| BITETTI TERESA MARIE | Pegawai | 02 Nov 2026 | Jual (-) | 46,609 | 20.87 | 972,730 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States
OSAKA, Japan & CAMBRIDGE, Mass., November 12, 2026--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States… |
| 30 Oct 2026 | Yahoo Finance |
Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were sharply lower Friday morning, d… |
| 30 Oct 2026 | Yahoo Finance |
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call
Takeda Pharmaceutical (NYSE:TAK) reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability. Core revenue totaled j… |
| 29 Oct 2026 | Yahoo Finance |
Takeda (TAK) Q2 2026 Earnings Call Transcript
Core revenue declined 1% as mature portfolio headwinds offset new product growth. |
| 29 Oct 2026 | Yahoo Finance |
Takeda H1 profit rises on cost savings, currency gains; hikes FY outlook
Investing.com-- Takeda Pharmaceutical Co., Ltd. (TYO:4502) reported a stronger operating profit for the first half on Thursday, aided by increased cost-cutting measures and sustained weakness in the yen, which boosted returns from overseas sales. |
| 29 Oct 2026 | Yahoo Finance |
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones
OSAKA, Japan, October 29, 2026--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide)… |
| 25 Oct 2026 | Yahoo Finance |
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announced multiple clinical data… |
| Hasil Dividen (DY TTM) | 4.61% |
| Purata Hasil Dividen 5T | 2.46% |
| Nisbah Pembayaran | 289.45% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 30 Mar 2023 | 15 Mar 2023 | 10 Jul 2023 | 0.30996 Tunai |
| 29 Sep 2022 | 13 Sep 2022 | 12 Dec 2022 | 0.329553 Tunai |
| 30 Mar 2022 | 04 Mar 2022 | 11 Jul 2022 | 0.330062 Tunai |
| 29 Sep 2021 | - | 13 Dec 2021 | 0.396898 Tunai |
| 30 Mar 2021 | 15 Mar 2021 | 12 Jul 2021 | 0.406627 Tunai |
| 29 Sep 2020 | - | 11 Dec 2020 | 0.430533 Tunai |
| 30 Mar 2020 | - | 06 Jul 2020 | 0.419053 Tunai |
| 27 Sep 2019 | 09 Sep 2019 | 12 Dec 2019 | 0.411118 Tunai |
| 28 Mar 2019 | 16 Mar 2019 | 10 Jul 2019 | 0.417168 Tunai |
| 26 Sep 2018 | - | 13 Dec 2018 | 0.395501 Tunai |
| 27 Mar 2018 | - | 09 Jul 2018 | 0.40643 Tunai |
| 27 Sep 2017 | - | 11 Dec 2017 | 0.39946 Tunai |
| 29 Mar 2017 | - | 10 Jul 2017 | 0.39892 Tunai |
| 28 Sep 2016 | - | 12 Dec 2016 | 0.392415 Tunai |
| 29 Mar 2016 | - | 11 Jul 2016 | 0.43705 Tunai |
| 28 Sep 2015 | - | 11 Dec 2015 | 0.365323 Tunai |
| 27 Mar 2015 | - | 09 Jul 2015 | 0.365289 Tunai |
| 25 Sep 2014 | - | 11 Dec 2014 | 0.378342 Tunai |
| 26 Mar 2014 | - | 10 Jul 2014 | 0.443655 Tunai |
| 25 Sep 2013 | - | 12 Dec 2013 | 0.436978 Tunai |
| 26 Mar 2013 | - | 08 Jul 2013 | 0.457131 Tunai |
| 25 Sep 2012 | - | 13 Dec 2012 | 0.545983 Tunai |
| 27 Mar 2012 | - | 09 Jul 2012 | 0.563768 Tunai |
| 27 Sep 2011 | - | 12 Dec 2011 | 0.578629 Tunai |
| 28 Mar 2011 | - | 07 Jul 2011 | 0.555761 Tunai |
| 27 Sep 2010 | - | 13 Dec 2010 | 0.533229 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2023 | 0.310 | 1 | 2.17 |
| 2022 | 0.660 | 2 | 4.23 |
| 2021 | 0.804 | 2 | 5.90 |
| 2020 | 0.850 | 2 | 4.67 |
| 2019 | 0.828 | 2 | 4.20 |
| 2018 | 0.802 | 2 | 4.77 |
| 2017 | 0.798 | 2 | 2.81 |
| 2016 | 0.829 | 2 | 3.99 |
| 2015 | 0.731 | 2 | 2.92 |
| 2014 | 0.822 | 2 | 3.96 |
| 2013 | 0.894 | 2 | 3.88 |
| 2012 | 1.11 | 2 | 5.00 |
| 2011 | 1.13 | 2 | 5.15 |
| 2010 | 0.533 | 1 | 2.19 |
| Papar semua | |||
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |